CoChat

Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy

Tan, Lun, Zhang, Jifa, Wang, Yuxi, Wang, Xiye, Wang, Yanyan, Zhang, Zhixiong, Shuai, Wen, Wang, Guan, Chen, Juncheng, Wang, Chengdi, Ouyang, Liang, Li, Weimin · 2022 · Journal of Medicinal Chemistry

The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.

Abstract

Epidermal growth factor receptor (EGFR) is of great significance in mediating cell signaling transduction and tumor behaviors. Currently, third-generation inhibitors of EGFR, especially osimertinib, are at the clinical frontier for the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC). Regrettably, the rapidly developing drug resistance caused by EGFR mutations and the compensatory mechanism have largely limited their clinical efficacy. Given the synergistic effect between EGFR and other compensatory targets during tumorigenesis and tumor development, EGFR dual-target inhibitors are promising for their reduced risk of drug resistance, higher efficacy, lower dosage, and fewer adverse events than those of single-target inhibitors. Hence, we present the synergistic mechanism underlying the role of EGFR dual-target inhibitors against drug resistance, their structure-activity relationships, and their therapeutic potential. Most importantly, we emphasize the optimal target combinations and design strategies for EGFR dual-target inhibitors and provide some perspectives on new challenges and future directions in this field.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.1c01714

Cites

170 of 170 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 170 references

Research works printed but not linked: 4

  1. Swarbrick M. E., 2012, Kinase Drug Discovery, 79
  2. Viloria-Petit A., 2001, Cancer Res., 61, 5090
  3. Marais R., 1996, Cancer Surv., 27, 101
  4. Matheson S. L., 2001, J. Pharmacology Experimental Therapeutics, 296, 832

Cited by

See all 89

Metadata

Authors
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., Ouyang, L., & Li, W.
Affiliations
  • Sichuan University (CN)
  • Department of Respiratory and Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China
Corresponding author
  • Wang, Chengdi
  • Ouyang, Liang
  • Li, Weimin
Venue
Journal of Medicinal Chemistry
Published
2022-03-21
Volume
65
Issue
7
Pages
5149-5183
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W4221034213
Cited by
88
References
170
Citations by year
2026: 16 · 2025: 21 · 2024: 25 · 2023: 20 · 2022: 6
FWCI
11.77
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministry of Science and Technology of the People's Republic of China (2018ZX09201018-021)
  • National Natural Science Foundation of China (81874290, 81903502, 81922064, 82073318)
  • National Clinical Research Center for Geriatrics, Sichuan University (Z20201004)
  • Sichuan Science and Technology Program (2019YFS0003)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
Keywords
epidermal growth factor receptor, dual inhibitors, EGFR-mutant non-small cell lung cancer, osimertinib, drug resistance, compensatory signaling, structure-activity relationship
MeSH terms
Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. https://app.cochat.ai/papers/10.1021/acs.jmedchem.1c01714
The paper
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., Ouyang, L., & Li, W. (2022). Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c01714

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.